Patient case (clinical description): The patient is a 38-year-old man with cough and body ache that started 3 days ago.  He had fever and chills at the beginning and has low grade fever at the time of visit. He feels tired and sleepy. His body ache and myalgia get better after using Tylenol. The PCR test for Covid is positive. His vital signs are within normal limits with a body temperature of 37.9 C. There is no lymphadenopathy or white exudates in the pharynx.

Patient's own account: I was feeling really sick the other day, to the point that I showed up at the doctor's office. I was coughing, and my body was hurting for 3 days. I had a fever and chills and felt tired and sleepy. I got better after using Tylenol. They did a PCR Covid test on me, and it was positive! My vitals were normal, and my temperature was 37.9 C. I had no swelling around my neck or white spots on the back of my throat.

Clinical trial: A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacodynamics for the Treatment of COVID-19.

Eligibility criteria:
Inclusion Criteria:

          -  Is a male or female greater than or equal to18 years of age at Screening;

          -  Is willing and able to sign and date (or has a legally authorized representative
             willing to sign and date) a written (or electronic) informed consent form or provide
             equivalent consent per Food and Drug Administration guidelines on COVID-19 clinical
             trials;

          -  Has a documented, laboratory-confirmed severe acute respiratory syndrome coronavirus-2
             (SARS-CoV-2) infection as determined by polymerase chain reaction, a SARS-CoV-2
             antigen test, or another commercial or public health assay, within 3 days (72 hours)
             of randomization;

          -  Has COVID-19 of moderate severity, as defined by the following: Positive testing by
             standard reverse transcription polymerase chain reaction assay or equivalent testing;
             Symptoms of illness with COVID-19, which could include any of the following: cough,
             fever, shortness of breath, chest pain, abdominal pain, nausea/vomiting, diarrhea,
             body aches, weakness/fatigue, or new loss of taste or smell; Clinical signs suggestive
             of illness with COVID-19, such as respiratory rate greater than or equal to 20 breaths
             per minute, saturation of oxygen greater than 93% on room air at sea level, or heart
             rate greater than or equal to 90 beats per minute; and No clinical signs indicative of
             severe or critical severity.

        Exclusion Criteria:

          -  Has an NIAID ordinal scale score <5;

          -  Is on high-flow oxygen or any form of noninvasive ventilation, excluding continuous
             positive airway pressure (CPAP) alone for sleep disorders (e.g., obstructive sleep
             apnea);

          -  Has significant cardiovascular disease, defined by myocardial infarction, arterial
             thromboembolism, or cerebrovascular thromboembolism within 3 months prior to
             randomization; symptomatic dysrhythmias or unstable dysrhythmias requiring medical
             therapy; angina requiring therapy; symptomatic peripheral vascular disease; New York
             Heart Association Class 3 or 4 congestive heart failure; Grade 3 hypertension
             (diastolic blood pressure greater than or equal to 100 mmHg or systolic blood pressure
             greater than or equal to 160 mmHg); history of congenital prolonged QT syndrome, or
             known dyslipidemia;

          -  Is currently taking any investigational products, other than the study drug;

          -  Has any other condition that, in the opinion of the Investigator, could interfere with
             (or for which the treatment might interfere with) the conduct of the clinical trial or
             interpretation of the clinical trial results or that would place the subject at undue
             risk by participating in the clinical trial.
No condition on gender to be admitted to the trial.
No healthy subjects accepted to join the trial.
Subject must be at least 18 Years old.


Eligibility (NLI label): Entailment